https://www.avient.com/resources/safety-data-sheets?page=48
X ET 6600 Natural - Nylon 6,6 glass
https://www.avient.com/sites/default/files/2020-07/avient-abac-english-200720.pdf
subject= http://avient.ethicspoint.com 5 Quick Reference: ABAC DOs AND DON’Ts DO ✓ Know that Avient prohibits any form of bribery and corruption and does not allow facilitation payments ✓ Be familiar with applicable aspects of our ABAC Policies and communicate them to subordinates and third parties ✓ Ask questions if the Policies or actions required to be taken are unclear ✓ Promptly report violations or suspected violations to your supervisor, the Legal Department or the Ethics Hotline ✓ Know that “value” is not necessarily measured in monetary terms ✓ Know that bribes can include the following: • Cash and cash equivalents (gift cards or gift certificates) • Gifts, entertainment and hospitality where there is no clear business purpose or they are in excess of business needs • Payment of travel expenses or vacations • Paying a government official to ignore an applicable customs requirement or to accelerate a tax refund • Personal services, favors, and loans • Offers of employment or other benefits to a family member or friend of the individual who has influence • Political party and candidate contributions • Charitable donations and sponsorships • Other less obvious items include in-kind contributions, investment opportunities and favorable or steered subcontracts ✓ Know that the prohibition applies whether an item would benefit the individual directly or another person, such as a family member, friend or business associate ✓ Keep books, records, and accounts in reasonable detail, and accurately and fairly reflect the transaction ✓ Conduct due diligence on agents, distributors, and other third parties prior to engagement and during the relationship and obtain Legal Department approval ✓ Properly manage and monitor business activities conducted through third-parties DON’T x Offer, promise, pay, or authorize the payment of anything of value to any government official and/or private sector employees to help Avient obtain or keep business or secure some other improper business advantage.
This prohibition applies whether the offer or payment is made directly or through another person x Make misleading, incomplete, or false entries in Avient’s books and records x Ignore red flags when dealing with third parties HOME | TOC North America Global Headquarters Avon Lake, United States 33587 Walker Road Avon Lake, OH, United States 44012 Toll Free: +1 866 765 9663 Phone: +1 440 930 1000 Fax: +440 930 3064 Asia Pacific Regional Headquarters Shanghai, China 2F, Block C 200 Jinsu Road Pudong, 201206 Shanghai, China Telephone: +86 (0) 21 6028 4888 Fax: +86 (0) 21 6028 4999 South America Regional Headquarters Sao Paulo, Brazil Av.
https://www.avient.com/resources/safety-data-sheets?page=4342
https://www.avient.com/resources/safety-data-sheets?page=19
https://www.avient.com/sites/default/files/2023-03/AVNT Q2 2022 Earnings Presentation - Website Version.pdf
S EC O N D Q UART ER 2022 RE S U LTS $122 $134 2021 2022 $0.87 $0.98 2021 2022 Q2 2022 PERFORMANCE (TOTAL COMPANY) 4 Sales Adjusted Operating Income $1,235 $1,302 2021 2022 + 5% Adjusted EPS + 10% + 13% (in millions) (in millions) (+ 10% excluding FX) (+ 16% excluding FX) (+ 20% excluding FX) Q2 2022 SEGMENT PERFORMANCE 5 CAI $624 $649 Sales ($ in millions) SEM Distribution $86 $94 Operating Income + 4% + 9% $404 $443 Sales $24 $27 Operating Income + 10% + 13% (1) $241 $244 Sales $37 $37 Operating Income + 1% Flat (+ 10% excluding FX) (+ 16% excluding FX) (+ 6% excluding FX) (+ 3% excluding FX) Q2 2021 $1,235 $122 Sustainable Solutions 17 7% 7 Healthcare 23 14% 5 Composites (ex Outdoor High Performance) 10 20% 4 Growth in Asia / LATAM 5 3% 1 Other 69 11% 5 Sub-total $1,359 10% $144 Outdoor High Performance Impact (9) (5) Wage Inflation and Overtime (7) Other Supply Chain Costs (2) Clariant Color Integration Synergies 7 Incentives, Other Employee Costs 4 FX (48) (7) Q2 2022 $1,302 5% $134 Q2 2022 SALES AND OPERATING INCOME (TOTAL COMPANY) 6 Sales Growth Rate Adjusted Operating Income$ millions Adjusted EBITDA Q2 EBITDA BRIDGE 7 Price increases more than offsets raw material and supply chain impacts Q2 2021 $ 159 Demand (29) $ millions CAI: Price / Mix 87 Inflation (58) SEM: Price / Mix 36 Inflation (24) Distribution: Price / Mix 45 Inflation (41) Net Price Benefit 45 Wage Inflation and Overtime (7) Other Supply Chain Costs (2) Clariant Color Integration Synergies 7 Incentives, Other Employee Costs 4 FX (7) Q2 2022 $ 170 China Lockdowns / Russia Impact $ (14) Outdoor High Performance (5) Transportation (5) 8 Q2 '21 Adjusted EPS 0.87$ Color, Additives and Inks 0.11 Specialty Engineered Materials 0.01 Distribution 0.03 Corporate Costs 0.01 F/X (0.05) Segment OI 0.11$ Interest Expense 0.03 Tax Rate (0.03) Q2 '22 Adjusted EPS 0.98$ Q2 EPS BRIDGE Key Updates • Provided progress on 2030 Sustainability Goals • Emphasized commitment to U.N.
EPS (ex Amort) 3.96$ 0.13$ 4.09$ (0.58)$ 3.51$ Pro Forma Leverage (12/31/2022E) Net Debt / Adjusted EBITDA 1.6x 3.4x 2.8x Forecast Dyneema Forecast + Dyneema Sale of Distribution Pro Forma 2022 TWO-YEAR LEVERAGE MODEL 16 3.5x 2.7x 1.6x 2.8x 2.4x 2.0x 2019PF 2020PF 2022E 2022PF 2023E 2024E Dyneema® AcquisitionClariant Color Acquisition (1) Pro forma for the acquisition of the Clariant Color business (2) Pro forma for the acquisition of Dyneema® and potential divestiture of Distribution, including repayment of senior notes due 2023 and Term Loan (1) (1) (2) OUR SPECIALTY JOURNEY CONTINUES 17 • Dyneema® brings leading technology and brand with the World’s Strongest Fiber™, deep history of application development and strong management team focused on specialty applications • Dyneema® transaction is aligned with our previously stated acquisition goal of expanding our composites and fiber capabilities • Similar to our other technology expansion acquisitions, Dyneema® allows us to leverage our invest-to-grow strategy • The possible sale of our Distribution business also presents potential benefits with respect to leverage and EBITDA margins 7% 46% 66% 86% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2015 2021 2022 PF % o f A dj u st ed E B IT D A (1 ) JVs Distribution Performance Products & Solutions Specialty (1) Adjusted EBITDA is EBITDA excluding corporate costs and special items (2) Pro forma for the acquisition of Dyneema® and potential divestiture of Distribution (2) Healthcare 4% Packaging 8% Consumer 10% Building & Construction 43% Industrial 15% Transportation 14% Energy 4% Telecom. 2% 2006 2022 Pro forma Healthcare 8% Packaging 23% Consumer 21% Building & Construction 10% Industrial 15% Transportation 9% Energy 4% Telecom. 4% Defense 6% END MARKET TRANSFORMATION TO LESS CYCLICAL INDUSTRIES ( W IT H DY N E E MA, E X .
Senior management believes the measures described above are useful to investors because they allow for comparison to Avient's performance in prior periods without the effect of items that, by their nature, tend to obscure Avient's operating results due to the potential variability across periods based on timing, frequency and magnitude.
https://www.avient.com/sites/default/files/resources/TRA%2520-%25202016%2520Plan%2520Summary.pdf
Company Address 17 Tideman Drive, Orangeville (Ontario) Report Details NPRI ID 2277 Facility Name Orangeville Plasticizer Facility Address 15 Tideman Drive, Orangeville (Ontario) Update Comments Activities Contacts Select the Facility Contacts Facility Contacts Please assign the appropriate contact under each category below.
Facility Information Facility Name: * Orangeville Plasticizer NAICS Code: * 326198 NPRI Id: * 2277 ON Reg 127/01 Id Facility Mailing Address Delivery Mode General Delivery PO Box Rural Route Number Address Line 1 15 Tideman Drive City * Orangeville Province/Territory ** Ontario Postal Code: ** L9W3K3 Physical Address Address Line 1 15 Tideman Drive City Orangeville Province/Territory ** Ontario Postal Code ** L9W3K3 Additional Information Land Survey Description National Topographical Description NPRI Facility Location Latitude (decimal degrees) * 43.91330 Longitude (decimal degrees) * 80.11580 UTM Zone UTM Easting UTM Northing Contact Validation The information in this section was copied from the Single Window Information Manager (SWIM) at the time the plan summary was created.
https://www.avient.com/products-1
From the simple feel of a toothbrush, to the protective casing on an X-ray machine, plastics play a crucial role in our daily lives.
https://www.avient.com/news/archives?page=41
GUANGZHOU, China – May 21, 2019 – At CHINAPLAS 2019 this week, PolyOne is sponsoring Design X Innovation, three events co-located at the fairgroun
https://www.avient.com/sites/default/files/2021-09/avnt-q2-2021-earnings-presentation.pdf
D is t. ) K W R P P G A V Y F U L R P M G C P H X L F M C H U N IF F E C L A S H K R A E M N C E S C L A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of July 28, 2021 Avient reflects 2021 estimated revenue of $4,650M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators.
Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 81% Median: 78% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $580M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of July 28, 2021 87 90 86 82 80 78 73 87 82 82 79 79 78 78 77 76 71 67 46 A vi en t K W R P P G A V Y F U L R P M G C P F M C U N V R C E IF F A S H E C L B N R E M N H X L H U N K R A S C L A L B (6) Source: Peer data per Bloomberg market data as of July 28, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the median of other selected chemical / specialty companies.
With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 25 Avient reflects 2021 estimated EBITDA of $580M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 18.5 15.1 15.1 14.0 11.0 10.4 29.5 28.2 23.9 18.7 12.4 12.2 11.1 9.3 9.2 9.2 7.6 7.6 6.0 A vi en t K W R P P G A V Y R P M F U L G C P A L B H X L E C L IF F F M C B N R A S H S C L E M N U N V R K R A C E H U N Median: 11.1xMedian: 14.6x SUMMARY: WHY INVEST IN AVIENT?
https://www.avient.com/sites/default/files/2021-05/avnt-first-quarter-2021-earnings-presentation.pdf
D is t. ) K W R R P M P P G A V Y F U L G C P IF F H X L F M C F O E H U N E C L K R A E M N A S H C E S C L G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of April 27, 2021 Avient reflects 2021 estimated revenue of $4,300M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators.
Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of April 27, 2021 87 89 87 86 82 81 76 88 87 84 82 81 78 77 77 77 76 73 70 69 50 19 A vi en t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H C E B N R F O E E M N G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of April 27, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers.
With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 20 Avient reflects 2021 estimated EBITDA of $560M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 10.2 17.7 16.0 14.9 14.6 11.6 11.1 26.7 24.0 22.8 14.3 12.7 11.5 11.2 11.1 11.0 10.3 10.1 9.5 9.4 8.3 7.0 A vi en t K W R A V Y R P M P P G G C P F U L A L B H X L E C L IF F F M C B N R A S H G R A F O E S C L E M N U N V R C E K R A H U N Median: 11.1xMedian: 14.8x SUMMARY: WHY INVEST IN AVIENT?